Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release
P. Rogliani (Roma (RM), Italy), B. Ritondo (Roma (RM), Italy), F. Facciolo (Roma (RM), Italy), M. Matera (Naples (NA), Italy), I. Nikolaev (Basel (CH), Switzerland), L. Calzetta (Parma (PR), Italy)
Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
P. Rogliani (Roma (RM), Italy), B. Ritondo (Roma (RM), Italy), F. Facciolo (Roma (RM), Italy), M. Matera (Naples (NA), Italy), I. Nikolaev (Basel (CH), Switzerland), L. Calzetta (Parma (PR), Italy). Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on neuronal inflammation and acetylcholine release. 551
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Indacaterol acetate, glycopyrronium bromide, and mometasone furoate: effect on human airway inflammation Source: Virtual Congress 2021 – Airway pharmacology: translational and basic science Year: 2021
Budesonide is better retained in airway tissue than fluticasone propionate and mometasone furoate due to the formation of lipophilic, slowly hydrolyzed budesonide esters Source: Eur Respir J 2003; 22: Suppl. 45, 281s Year: 2003
Fluticasone propionate is as potent but more receptor-selective than mometasone furoate Source: Eur Respir J 2001; 18: Suppl. 33, 95s Year: 2001
Variable lipophilicity of budesonide: Comparison with fluticasone propionate, mometasone furoate, and ciclesonide Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Mometasone furoate is a less specific glucocorticoid than fluticasone propionate Source: Eur Respir J 2002; 20: 1386-1392 Year: 2002
Higher cellular retention and activity after pulse exposure by budesonide (BUD) than fluticasone propionate (FP) and mometasone furoate (MF) Source: Eur Respir J 2001; 18: Suppl. 33, 158s Year: 2001
Extrafine glycopyrronium bromide (GB) in addition to extrafine beclomethasone dipropionate/formoterol fumarate (BDP/FF) in uncontrolled asthmatic patients Source: International Congress 2018 – Innovative therapies in asthma and COPD Year: 2018
Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma Source: Eur Respir J 2014; 43: 773-782 Year: 2014
Pharmacokinetics of indacaterol, glycopyrronium and mometasone furoate following once daily inhalation as a fixed-dose combination in healthy subjects Source: International Congress 2019 – Clinical studies of asthma treatments Year: 2019
Role of budesonide, formoterol fumarate and aclidinium bromide in the inflammaging of airway epithelial cells Source: International Congress 2017 – Cigarette smoke and particulate matter: basic science and clinical aspects Year: 2017
Clinical efficacy of once-daily mometasone furoate in children with persistent asthma switched from treatment with fluticasone propionate Source: Annual Congress 2011 - Airways disease comorbidities and general aspects Year: 2011
Budesonide is retained in the airways longer than mometasone furoate due to the reversible formation of lipophilic budesonide fatty acid esters - significance for asthma therapy Source: Eur Respir J 2002; 20: Suppl. 38, 53s Year: 2002
Inhibitory effects of formoterol, budesonide and tiotropium bromide on human neutrophils in vitro Source: Eur Respir J 2003; 22: Suppl. 45, 286s Year: 2003
Safety of fluticasone furoate (FF), an inhaled corticosteroid in combination with vilanterol (VI), a long-acting beta agonist in management of COPD exacerbations Source: Annual Congress 2012 - COPD treatments: efficacy and safety Year: 2012
Comparison of inhaled ciclesonide, fluticasone propinate and fluticasone propionate + salmeterol in maintaining asthma control Source: Annual Congress 2009 - Drug treatment of childhood asthma: the controversies and the issues Year: 2009
Mometasone furoate delivered via Breezhaler and Twisthaler in patients with asthma Source: International Congress 2019 – Asthma: outcomes of clinical trials and cohorts Year: 2019
Once-daily versus twice-daily administration of mometasone furoate dry powder inhaler (MF-DPI) improves lung function in children with asthma previously maintained on inhaled corticosteroids (ICS) Source: Eur Respir J 2004; 24: Suppl. 48, 164s Year: 2004
Administration of mometasone furoate once daily in the evening is as effective as mometasone furoate administered twice daily in improving lung function in patients with mild to moderate persistent asthma Source: Eur Respir J 2003; 22: Suppl. 45, 33s Year: 2003
Comparative efficacy and safety of mometasone furoate dry powder inhaler and budesonide Turbuhaler(R) Source: Eur Respir J 2001; 17: 1332-1333 Year: 2001
Efficacy of the novel inhaled corticosteroid, fluticasone furoate (FF)/long-acting beta2 -agonist, vilanterol (VI) combination in reducing COPD exacerbations Source: Annual Congress 2012 - Trials in COPD: novel treatments and insights Year: 2012